Experimental isolation and transplantation of hepatocytes with the use of antibody against interleukin-2 receptor (daclizumab) as immunosuppressive agent (Journal article)

Tsiolis, I./ Papalois, A./ Loukopoulos, I./ Gravvanis, A./ Lykoudis, E./ Theodossopoulou, E./ Chairakakis, A./ Dimitroulopoulos, D./ Sfiniadakis, I./ Vassiliou, I./ Felekouras, E./ Dedeilias, P./ Kontogiorgi, M./ Papadimitriou, L./ Papadimitriou, I.


INTRODUCTION: Daclizumab (Dmab) is a genetically engineered humanized IgG1 monoclonal antibody that binds to the alpha chain of the interleukin-2 receptor (Tac, CD25, p55) expressed on activated human T lymphocytes. Dmab has been used in a clinical protocol of islet transplantation with satisfactory results. The aim of the present study was to evaluate the use of an antibody against the interleukin-2 receptor (Dmab) as an immunosuppressive agent in an experimental model of hepatocyte allotransplantation (allo-Tx) in rats with fulminant hepatic failure (FHF). MATERIALS AND METHODS: Six Wistar rats were used as donors and 48 Lewis rats as recipients: four groups of 12 animals each with induction of FHF and 24 hour later hepatocyte Tx--group A: no treatment; group B: cyclosporin (20 mg/kg days 0 to 5 and 10 mg/kg days 6 to 15); group C: Dmab (0.05 mg day of Tx and 0.05 mg day 7); and group D: Dmab and cyclosporine. Hepatocytes were transplanted intrasplenically. Animals were followed for 15 days. RESULTS: Statistical analysis showed better survival among groups C (83%, MST = 13) and D (92%, MST = 14.25) compared to groups A (max 72, MST = 1.5) or B (50%, MST = 9). Survival in group D was better but not significantly than group C. Biochemical evaluation and histology confirmed satisfactory function and engraftment, respectively. CONCLUSION: This experimental model showed the safe, effective use of Dmab.
Institution and School/Department of submitter: Πανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικής
Keywords: Animals,Antibodies, Monoclonal/*therapeutic use,Antibodies, Monoclonal, Humanized,Graft Survival,Hepatocytes/*cytology/*transplantation,Immunoglobulin G/*therapeutic use,Immunosuppressive Agents/*therapeutic use,Liver Failure, Acute/*surgery,Male,Models, Animal,Rats,Rats, Inbred Lew,Rats, Wistar,Receptors, Interleukin-2/immunology,Spleen,Transplantation, Homologous/*immunology
URI: http://olympias.lib.uoi.gr/jspui/handle/123456789/21729
ISSN: 0041-1345
Link: http://www.ncbi.nlm.nih.gov/pubmed/15919507
http://ac.els-cdn.com/S0041134505002137/1-s2.0-S0041134505002137-main.pdf?_tid=6c7f5e0f151836aebe43c26e30efa7b9&acdnat=1333466359_a0997b78a318651a2cc299834eb56de3
Appears in Collections:Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά)

Files in This Item:
File Description SizeFormat 
Tsiolis-2005-Experimental isolati.pdf50.56 kBAdobe PDFView/Open    Request a copy



 Please use this identifier to cite or link to this item:
http://olympias.lib.uoi.gr/jspui/handle/123456789/21729
  This item is a favorite for 0 people.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.